BlackRock Virginia Municipal Bond Trust (BHV) Stock Price

10.96 ▲ +0.08 (+0.74%)
Open: 11.0206 Vol: 12.38K Day's range: 10.89 - 11.0206 Mar 02, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
BHV Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 10.76▲ 10.76▲ 10.76▲ 10.88▲ 10.83▲
MA10 10.66▲ 10.66▲ 10.66▲ 10.83▲ 10.69▲
MA20 10.61▲ 10.61▲ 10.61▲ 10.78▲ 10.86▲
MA50 10.87▼ 10.91▼ 10.92▼ 10.65▲ 10.60▲
MA100 10.82▼ 10.73▲ 10.74▲ 10.86▲ 10.84▲
MA200 10.82▼ 10.88▼ 10.87▼ 10.62▲ 11.07▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.045▲ 0.043▲ 0.043▲ 0.016▲ 0.008▲
RSI 55.418▲ 54.247▲ 54.010▲ 72.466▲ 57.311▲
STOCH 97.849▲ 97.849▲ 97.849▲ 93.969▲ 75.361    
WILL %R 0.000▲ 0.000▲ 0.000▲ -15.922▲ -28.947    
CCI 115.953▲ 115.953▲ 115.953▲ 195.779▲ 100.744▲
Latest Filters Detected On BHV
▲ RSI $BHV RSI(14) Crossed Above 70 Set Alert
▲ BREAK $BHV Price Breaks 30 Days High Set Alert
▲ BREAK $BHV Price Breaks 20 Days High Set Alert
▲ BREAK $BHV Price Breaks 10 Days High Set Alert
BlackRock Virginia Municipal Bond Trust News
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Monday, January 12, 2026 08:15 AM
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ ...
Biohaven Misses The Mark In Depression Trial, Stock Falls
Friday, December 26, 2025 12:20 AM
On Wednesday, Biohaven Ltd. (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD). The study did not meet its primary endpoint, a ...
Biohaven: Phase 2 Proof-of-concept Study With BHV-7000 Fails To Meet Primary Endpoint
Thursday, December 25, 2025 03:26 AM
(RTTNews) - Biohaven (BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder. The study did not meet its primary endpoint, a ...
BHV historical stock data
date open high low close volume
02/03/26 11.0206 11.0206 10.89 10.96 12,382
27/02/26 10.89 10.89 10.88 10.88 2,000
26/02/26 10.84 10.84 10.84 10.84 112
25/02/26 10.84 10.86 10.84 10.86 3,500
24/02/26 10.84 10.84 10.84 10.84 958
23/02/26 10.82 10.85 10.79 10.85 3,000
20/02/26 10.80 10.81 10.80 10.81 2,308
19/02/26 10.74 10.80 10.74 10.77 6,800
18/02/26 10.7826 10.7826 10.6901 10.75 7,162
17/02/26 10.64 10.78 10.64 10.77 2,300
Quote Details
52wk Low:10.01
52wk High:11.66
Vol:12.38K
Avg Vol(3m):67.7K
1Y Chng:+1.76%
1M Chng:+2.81%
Add to Watch List
More Information
Index N/A
Market Cap. 17.28M